Back to search results

Studying the Impact of Free Continuous Glucose Monitors for Type 2 Diabetes

This study is looking at how providing Continuous Glucose Monitors (CGMs) for free can help adults with poorly controlled type 2 diabetes. CGMs are small devices that track your blood sugar levels throughout the day. The study aims to see if having free access to CGMs improves blood sugar control (measured by A1c) and quality of life for people who might not otherwise be able to afford them. You may be able to join if you have type 2 diabetes, an A1c of 8.0 or higher, and have been taking insulin for at least a year. The study plans to enroll 17 participants.

Study design
This is a non-blinded, non-randomized study, meaning both you and the study staff will know you are receiving the CGM. It will involve about 17 participants.
What's involved
You would receive a CGM sensor and learn how to use it. You would replace the sensor every 14 days for 3 months, and have follow-up visits at 6 weeks and 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your blood sugar control and quality of life will be measured at 12 weeks and 24 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06658067

Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access

Recruiting
NAAges 18+InterventionalSupportive care
Yale University
~17 participants
Updated 2025-12-03 on ClinicalTrials.gov
What's tested:Continuous Glucose Monitor (CGM)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean Illness Intrusiveness Ratings Scale score (IIRS)
Measured over Baseline, 12 weeks, 24 weeks
+1 more outcome measured

Conditions

Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus - Poor Control

Explore related trials

Type 2 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Connecticut1

Study leadership

  • Kasia Lipska, MD MHS · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Justin A Dower, MD
[email protected]
(973) 901-4431
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Diagnosed with type 2 diabetes mellitus
A1c greater than or equal to 8.0 within two weeks of the time of enrollment
On insulin for at least one year +/- other antihyperglycemics
Ability and willingness to wear CGM for 14-day periods throughout the trial period
Ability and willingness to comply with provider-directed adjustments to medication regimen
Inability to afford CGM sensors

Exclusion

Insulin naïve
Diabetic ketoacidosis (DKA) in previous 6 months
End-Stage Renal Disease (ESRD)
Contraindications to CGM use
Active insurance plan that would provide enough of a subsidy for participant to feasibly purchase CGM sensors
Pregnancy

What this trial measures

  • Mean Illness Intrusiveness Ratings Scale score (IIRS)Baseline, 12 weeks, 24 weeks

    The IIRS is a useful, easy-to-apply tool that measures the degree of illness-induced disruptions in the 13 different aspects of life. Total score range from 13 (minimal intrusiveness) to 91 (extreme intrusiveness).

  • Mean Hemoglobin A1c concentrationBaseline, 12 weeks, 24 weeks

    Mean A1c concentration in mg/dL measured in blood samples